Small molecules which reverse Vemurafenib treatment
Canned Analysis
FAIR Metrics
0 evaluations
General Information
AccessionDCA00012009
TitleSmall molecules which reverse Vemurafenib treatment
DescriptionThe L1000 database was queried in order to identify small molecule perturbations which reverse the gene expression signature induced by Vemurafenib treatment in the SW1736 thyroid cancer cell line (vemurafenib-refractory cell line) - 6 Hours cell type.
Analysis URLhttp://amp.pharm.mssm.edu/L1000CDS2/#/result/58d1d631e467bea600fb8f52
Upload DateSeptember 20, 2017
Uploadermaayanlab
Metadata
Analysis Curatorcadimo
CREEDS IDdrug:2560
Cell TypeSW1736 thyroid cancer cell line (vemurafenib-refractory cell line) - 6 Hours
Drug NameVemurafenib
DrugBank IDDB08881
Organismhuman
SMILES IDCCCS(=O)(=O)Nc1ccc(c(c1F)C(=O)c1c[nH]c2c1cc(cn2)c1ccc(cc1)Cl)F
L1000CDS2 parameters
Directionreverse
Characteristic Direction parameters
Control SamplesGSM919379, GSM919380, GSM919381
Perturbed SamplesGSM919385, GSM919386, GSM919387
Tools used in the analysis
Dataset Accession
Characteristic Direction
Published March 2014
A geometrical multivariate approach to identify differentially expressed genes
26829
L1000CDS2
Published August 2016
An ultra-fast LINCS L1000 Characteristic Direction signature search engine
7756
Datasets used in the analysis
Keyword
Tool Name
GSE37441
Gene Expression Omnibus
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas.
42
FAIR Evaluation
Sorry, you must be signed in to evaluate this object.